PPC
NVO

Park Place Capital’s Novo Nordisk NVO Stock Holding History

Park Place Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$50.9K – 872
2025
Q4 		$50.9K Hold
1,000
– – 0.01% 325
2025
Q3 		$55.5K Sell
1,000
-947
-49% -$55.4K 0.01% 315
2025
Q2 		$136K Buy
1,947
+264
+16% +$18K 0.03% 239
2025
Q1 		$117K Buy
1,683
+348
+26% +$28.7K 0.03% 240
2024
Q4 		$115K Buy
1,335
+335
+34% +$36.2K 0.03% 255
2024
Q3 		$119K Buy
+1,000
New +$133K 0.03% 268
2023
Q4 		– Sell
-584
Closed -$53.1K – 971
2023
Q3 		$53.1K Buy
584
+50
+9% +$4.41K 0.02% 462
2023
Q2 		$43.2K Sell
534
-586
-52% -$47.9K 0.01% 514
2023
Q1 		$89.1K Hold
1,120
– – 0.03% 376
2022
Q4 		$76K Buy
+1,120
New +$65.7K 0.02% 413

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Park Place Capital's NVO Position: Q1 2026 in Review

Park Place Capital sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 1,000 shares — an estimated $50.9K sold.

Park Place Capital first reported a position in NVO in Q4 2022 and held it in 10 quarters. The position peaked at $136K in Q2 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Park Place Capital reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Park Place Capital sold 1,000 Novo Nordisk shares in Q1 2026, an estimated $50.9K.
  • Park Place Capital first reported a position in Novo Nordisk in Q4 2022 and held it in 10 quarters.
  • Park Place Capital's Novo Nordisk position peaked at $136K in Q2 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.